A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 40,500 shares of ITCI stock, worth $3.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,500
Previous 61,300 33.93%
Holding current value
$3.5 Million
Previous $4.2 Million 29.47%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$64.76 - $79.84 $14.7 Million - $18.2 Million
-227,621 Reduced 63.0%
133,673 $9.16 Million
Q1 2024

May 15, 2024

BUY
$64.37 - $75.65 $21 Million - $24.6 Million
325,722 Added 915.67%
361,294 $25 Million
Q4 2023

Feb 14, 2024

SELL
$46.37 - $73.65 $2.3 Million - $3.65 Million
-49,610 Reduced 58.24%
35,572 $2.55 Million
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $3.18 Million - $3.92 Million
61,089 Added 253.55%
85,182 $4.44 Million
Q2 2023

Aug 14, 2023

SELL
$54.67 - $66.44 $32.2 Million - $39.2 Million
-589,663 Reduced 96.07%
24,093 $1.53 Million
Q1 2023

May 15, 2023

SELL
$43.8 - $56.99 $2.11 Million - $2.74 Million
-48,107 Reduced 7.27%
613,756 $33.2 Million
Q4 2022

Feb 14, 2023

BUY
$44.07 - $54.45 $21 Million - $26 Million
477,231 Added 258.48%
661,863 $35 Million
Q3 2022

Nov 14, 2022

SELL
$42.7 - $59.99 $9.44 Million - $13.3 Million
-221,099 Reduced 54.49%
184,632 $8.59 Million
Q2 2022

Aug 15, 2022

SELL
$43.0 - $65.64 $8.31 Million - $12.7 Million
-193,301 Reduced 32.27%
405,731 $23.2 Million
Q1 2022

May 16, 2022

SELL
$38.74 - $62.09 $5.88 Million - $9.42 Million
-151,684 Reduced 20.21%
599,032 $36.7 Million
Q4 2021

Feb 14, 2022

SELL
$35.2 - $53.42 $15 Million - $22.7 Million
-425,749 Reduced 36.19%
750,716 $39.3 Million
Q3 2021

Nov 15, 2021

SELL
$28.72 - $42.49 $11.1 Million - $16.4 Million
-384,927 Reduced 24.65%
1,176,465 $43.9 Million
Q2 2021

Aug 16, 2021

BUY
$29.3 - $44.5 $1.92 Million - $2.91 Million
65,386 Added 4.37%
1,561,392 $63.7 Million
Q1 2021

May 17, 2021

BUY
$30.8 - $39.51 $2.17 Million - $2.78 Million
70,320 Added 4.93%
1,496,006 $50.8 Million
Q4 2020

Feb 16, 2021

BUY
$23.34 - $32.22 $7.99 Million - $11 Million
342,124 Added 31.57%
1,425,686 $45.3 Million
Q3 2020

Nov 16, 2020

BUY
$17.61 - $31.86 $10.2 Million - $18.5 Million
582,002 Added 116.04%
1,083,562 $27.8 Million
Q2 2020

Aug 14, 2020

BUY
$14.35 - $26.64 $3.48 Million - $6.45 Million
242,173 Added 93.36%
501,560 $12.9 Million
Q1 2020

May 15, 2020

SELL
$12.31 - $33.12 $4.45 Million - $12 Million
-361,527 Reduced 58.22%
259,387 $3.99 Million
Q4 2019

Feb 14, 2020

SELL
$7.26 - $38.49 $620,054 - $3.29 Million
-85,407 Reduced 12.09%
620,914 $21.3 Million
Q3 2019

Nov 14, 2019

BUY
$7.47 - $14.03 $2.74 Million - $5.14 Million
366,673 Added 107.96%
706,321 $5.28 Million
Q2 2019

Aug 14, 2019

BUY
$10.65 - $14.29 $2.63 Million - $3.53 Million
246,976 Added 266.51%
339,648 $4.41 Million
Q1 2019

May 15, 2019

SELL
$10.9 - $14.09 $10.4 Million - $13.5 Million
-955,461 Reduced 91.16%
92,672 $0
Q4 2018

Feb 14, 2019

BUY
$10.36 - $20.96 $2.8 Million - $5.66 Million
269,940 Added 34.69%
1,048,133 $11.9 Million
Q3 2018

Nov 13, 2018

SELL
$17.77 - $22.9 $9.66 Million - $12.4 Million
-543,531 Reduced 41.12%
778,193 $0
Q2 2018

Aug 10, 2018

BUY
$17.33 - $23.4 $2.9 Million - $3.91 Million
167,197 Added 14.48%
1,321,724 $0
Q1 2018

May 11, 2018

BUY
$15.16 - $25.49 $14.7 Million - $24.8 Million
972,589 Added 534.57%
1,154,527 $24.3 Million
Q4 2017

Feb 09, 2018

BUY
$14.27 - $16.79 $1.64 Million - $1.92 Million
114,606 Added 170.21%
181,938 $2.63 Million
Q3 2017

Nov 09, 2017

BUY
$10.77 - $22.1 $725,165 - $1.49 Million
67,332
67,332 $1.06 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.16B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.